key: cord-0823630-yt099y98 authors: Aranda, Judit; Oriol, Isabel; Martín, Miguel; Feria, Lucía; Vàzquez, Núria; Rhyman, Nicolás; Vall-Llosera, Estel; Pallarés, Natàlia; Coloma, Ana; Pestaña, Melani; Loureiro, Jose; Güell, Elena; Borjabad, Beatriz; León, Elena; Franz, Elena; Domènech, Anna; Pintado, Sara; Contra, Anna; Cortés, María del Señor; Chivite, Iván; Clivillé, Raquel; Vacas, Montserrat; Ceresuela, Luis Miguel; Carratalà, Jordi title: Long-term impact of COVID-19 associated acute respiratory distress syndrome date: 2021-08-13 journal: J Infect DOI: 10.1016/j.jinf.2021.08.018 sha: f5229aa5c5081d5c3d7eee5e7dda5124f8cb9017 doc_id: 823630 cord_uid: yt099y98 OBJECTIVES: To determine the health status, exercise capacity, and health related quality of life (HRQoL) of COVID-19 associated acute respiratory distress syndrome (ARDS) survivors, 8 months after diagnosis. METHODS: All eligible patients were interviewed and underwent a physical examination, chest X-ray, and 6-minute walk test (6MWT). Scales to evaluate post-traumatic stress disorder, depression, anxiety, and HRQoL were applied. RESULTS: Of 1,295 patients, 365 suffered ARDS and 166 survived to hospital discharge. Five died after discharge and 48 were lost to follow-up. Of the 113 remaining patients, 81% had persistent symptoms. More than 50% of patients completed less than 80% of the theoretical distance on the 6MWT, 50% had an abnormal X-ray and 93% of patients developed psychiatric disorders. Mean SF-36 scores were worse than in the general population. After multivariate regression analysis, female sex, non-Caucasian race, and Charlson index>2 were independent risk factors for a worse mental health component summary score on the SF-36, and age was associated with a better prognosis. Female sex and chronic obstructive pulmonary disease were independently associated with a worse physical component summary score. CONCLUSION: COVID-19 associated ARDS survivors have long-term consequences in health status, exercise capacity, and HRQoL. Strategies addressed to prevent these sequelae are needed. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 2019 (COVID-19) that emerged in Wuhan, China, and spread rapidly across the world, causing a pandemic in just a few weeks (1) . Although most patients with COVID-19 will have a mild, selflimiting illness, up to 20% develop severe pneumonia and acute respiratory distress syndrome (ARDS) that can necessitate hospitalization, intensive care, and mechanical ventilation (2) . In recent months, much progress has been made in understanding the epidemiology, transmission mechanisms, clinical feature, in-hospital complications, and groups most at risk of a poor evolution and death due to COVID-19 (2) (3) (4) . Furthermore, multiple studies have been carried out to identify antiviral and immune modulating treatment options (2,3,5-7). However, the long-term consequences of COVID-19 are less clear, partly due to its short history, and partly due to the difficulty in monitoring patients after hospital discharge in a severely strained health care system. Some authors have speculated that the consequences of COVID-19 could be similar to those produced by the severe acute respiratory syndrome coronavirus (SARS-CoV), and the Middle East respiratory syndrome coronavirus (MERS-CoV). Both viruses have a close phylogenetic relationship with SARS-CoV-2 and are probably also similar in terms of clinical sequelae, respiratory function, psychiatric disorders, and health related quality of life (HRQoL) (8). In addition, previous studies among ARDS survivors have detected a high prevalence of cognitive impairment and reduced functional status and HRQoL (9,10). The few published studies that address the long-term outcomes of COVID-19 have included patients with a broad clinical spectrum of COVID-19 disease and have not focused on the most seriously ill (11-13). In this prospective study, we aimed to determine the clinical outcomes, exercise capacity, psychiatric disorders, and long-term HRQoL of patients with COVID-19 who developed ARDS and survived to hospital discharge. We performed a follow-up prospective single-centre study nested in a large multicentre prospective cohort of hospitalized adults with COVID-19 (COVID-MetroSud). The study was conducted at the Complex Hospitalari Moisés Broggi, a 350-bed public hospital that serves an area of 425,000 inhabitants in Barcelona, Spain. All patients were adults (>18 years old) admitted with reversetranscription-polymerase chain reaction (RT-PCR) proven SARS-CoV-2 infection and severe COVID-19 pneumonia between 28 February and 15 April 2020. We included only those patients who had suffered ARDS during hospital admission and survived to hospital discharge, and we excluded those who were institutionalized or admitted to hospital at the time of follow-up, refused to participate, could not be contacted after three calls, and lived outside the area covered by the hospital. All patients were informed of the study and signed the informed consent. The study conformed to the STROBE checklist and was approved by the ethics committee of the coordinating centre (Bellvitge University Hospital) in accordance with Spanish legislation. All procedures complied with the ethical standards of the Helsinki Declaration (PR140/20). The acute phase of the SARS-CoV-2 infection was considered the first day of symptom onset to hospital discharge. We recorded demographic and epidemiological data, sociofunctional status, comorbidities, clinical data, radiological findings, laboratory tests, and details of intensive care unit (ICU) admission, including orotracheal intubation, duration admitted (days), complications, and treatment. Data were recorded on a secure web-based software platform for online databases (REDCap) (14). Patients were assessed at a follow-up visit between November 2020 and December 2020. This visit included a comprehensive medical evaluation, clinical data collection focused on persistent symptoms, the degree of dyspnea according to the modified British Medical Research Council (mMRC) dyspnea scale (15) , and a complete physical examination. Patients were also asked about returning to their usual physical and work activity, as well as whether a close family member had died from COVID-19. All patients who were able to walk unaided completed a 6-minute walk test (6MWT), following the criteria of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) (16) . Median peripheral oxygen saturation (SpO 2 ) was recorded at baseline and after completing the 6MWT, as was the distance walked, in meters. The formula reported by Enright et al. (17) was used to calculate the percentage of meters completed based on the theoretical maximum. Any reasons for being unable to complete the test were recorded. Dyspnea on completion of the 6MWT was assessed using the Borg Rating Scale of Perceived Exertion (18) . We then verified whether patients had undergone a chest X-ray after hospital discharge. If not, one was requested to ensure that all patients had at least one follow-up chest X-ray. Information from chest computed tomography (CT) and pulmonary function tests (PFTs) was also collected when available. ARDS was defined according to the Berlin criteria as the appearance or worsening of respiratory failure associated with a known clinical event (23) . This required an oxygen arterial pressure (PaO 2 ) / inspired fraction of oxygen (FiO 2 ) ratio ≤300 mmHg, associated with radiology with the appearance of bilateral pulmonary opacities not explained by effusions, atelectasis, or masses. Length of hospital stay was described as the total number of days from admission to hospital discharge. Length of ICU stay was defined as the total number of days spent in critical care. Patient characteristics are presented as the number of cases and percentages for categorical variables and as means and standard deviation (SD) or median and interquartile range (IQR) for continuous variables. Fisher's exact test or Pearson's chi-squared test was used to assess the relationship between categorical variables. The student t-test or Mann-Whitney U test was used to compare continuous variables. We then used simple linear regression models to identify factors associated with the MCS and PCS scores of the SF36 questionnaire. Variables were included in the multivariate models if there were non-modifiable (i.e., age, sex, and race) and showed an association (p < 0.2) in the univariate analysis. Results are reported as beta values and 95% confidence intervals. All analyses were performed with a two-sided significance level of 0.05 and conducted using R, version 3.6.3 (cran.r-project.org) (24) . In total, 1,295 patients were admitted for COVID-19, of whom 365 suffered ARDS. Among the ARDS group, 199 died before discharge leaving 166 survivors of COVID-19-associated ARDS. During follow-up, 5 died and 48 did not attend visits, giving a final cohort of 113 patients. Most were male (70%) and had a median age of 64 years (IQR 54-72). Their demographic and clinical data are shown in Table 1 . Follow-up visits occurred a median of 240 days (IQR 230-246) from the first positive RT-PCR for SARS-CoV-2. Table 2 shows that 80% of patients reported at least one persistent symptom, predominantly dyspnea (55%), arthromyalgia (50%), moderate to severe asthenia (45.5%), subjective memory loss (42.5%), and subjective lack of concentration (40.7%). Moreover, 57% of patients had not recovered their physical health prior to admission. Only 9.8% required further hospital admission after discharge. presented some degree of depression, almost 50% suffered moderate to severe PTSD, and 34% had state anxiety at or above the 75 percentile. Concerning HRQoL, as shown in Figure 1 , the mean SF36 scores were worse following admission to hospital with COVID-19 and ARDS than in the general population for each of the eight dimensions, irrespective of sex. Table 1 ). In this prospective and comprehensive follow-up study of patients who developed ARDS during admission for COVID-19, we found that 80% had at least one persistent symptom 8 months after diagnosis. The most common of these were dyspnea and arthralgia. have relied on shorter follow-up periods and have reported varying prevalence rates for symptoms (11,12,25). Our results match those from a Chinese cohort (11), in which 74%-86% of patients had at least one persistent symptom, with 26%-36%of patients in the most severe group having dyspnea with an mMRC score >1 at 6 months. Similar results have been published by Meije et al. at 45days' follow-up, although at 7 months, they report 25% fewer persistent symptoms than in our study (25) . However, it is striking that Bellal et al. reported that fewer than 5% of patients had sequelae at 3-4 months. These wide differences may be because the entire population with COVID-19 was included in their study, while we only included the most ill patients. This would be consistent with the fact that our results are similar to those of previous studies published in patients with ARDS of different etiologies, in which 56%-84% of patients are reported to have persistent symptoms at 12 months (26) (27) (28) (29) . Regarding exercise capacity measured by the 6MWT, more than half of the patients completed <80% of the theoretical distance, adjusted for age. that the inability to exercise was mainly due to extrapulmonary disease, such as impaired muscle function (29) . Pathological radiological findings were present in a half of the cases that had imaging after hospital discharge. Similarly, Huang et al. describe radiological abnormalities in approximately 50% of patients at 6 months (11). By contrast, pathological findings were identified in only 20% of ARDS survivors, probably because these latter results were analysed 12 months after hospital discharge (29) . In our cohort, chest CT was performed in less than a third of patients; had it been performed in all patients, we may have been better placed to define the radiological abnormalities. In our study, 77% of patients undergoing a PFT had a DLCO <80%. The DLCO is the parameter most affected in Chinese (11) and Italian (12) cohorts of COVID-19 survivors, but both have fewer patients with a DLCO <80% (22% and 67%, respectively). This difference could be explained by the lower disease severity in the Chinese (11) and Italian (12) cohorts. Yet, surprisingly, only 56% of patients with the most severe disease in the study by Huang et al. had low DLCOs (11). Our result is still consistent with previous studies of ARDS survivors with different aetiologies and of SARS/MERS survivors affected by severe pneumonia and/or requiring ICU admission. This suggests that pulmonary sequelae may be more related to the appearance of ARDS than to the disease itself (26, (28) (29) (30) (31) (32) (33) . A total of 93% of patients had developed a mental health disorder by 8months' follow-up main disorders assessed were PTSD, depression, and anxiety, and all were present at levels considerably higher than published elsewhere (11, 25, 34) . The differences are also difficult to compare because we analyzed different psychiatric disorders and did not consider a subgroup of who suffered encephalopathy during hospital admission. Nevertheless, the trend seems to indicate that the most severe cases of COVID-19 present a higher risk of mental disorders in the medium term. Previous studies have focused on neurological and psychiatric disorders in patients with COVID-19 (mild to severe) and have found a similar prevalence of PTSD and depression just before hospital discharge (35, 36) . Some authors have hypothesized that this may be related to brain involvement of COVID-19 itself (37). However, psychiatric disorders must be analysed in the global context of the pandemic, which has led to significant changes in lifestyle, economy, work, and social relationships. In fact, the high percentage of PTSD is comparable to that described in studies conducted in survivors of wars and catastrophes (38, 39) . Similar to the mental health problems, the HRQoL of survivors was worse than in the general population. This is also consistent with previous studies among SARS and MERS survivors, as well as among patients affected by ARDS of different aetiologies (9,29,40). Moreover, high comorbidity and COPD were independently associated with worse scores in the MCS and PCS, respectively. A new and striking finding of our study was that Latino patients presented with worse outcomes (e.g., dyspnea, the 6MWT, MCS, and IES-R) at 8 months after COVID-19. These results should be explored in more detail by adding socioeconomic data or conducting multicentre studies to account for the specific characteristics of the Latino population in our geographic area. The main strength of this study lies in the prospective and comprehensive data collection for a large cohort of patients with severe COVID-19 who survived ARDS. We are also unaware of any other study that has assessed the survivors of COVID19-associated ARDS globally in physical and mental domains beyond 6 months' follow-up. However, the study has some equally limitations that should be noted. First, this was a single-centre study, and as such, our findings may lack generalizability by failing to reflect the epidemiology of different centres and/or geographical areas. Second, socioeconomic variables were not collected from patients, which may have influenced the outcomes. Finally, we were unable to perform PFT and CT studies in most patients. In summary, survivors of COVID-19 associated ARDS had poor exercise capacity, health status, and lower HRQoL scores after 8 months compared with the general population. More than 90% presented with mental health disorders, including PTSD, depression, and anxiety. A multidisciplinary approach should be promoted to improve the care of patients with the sequelae of COVID-19. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development COVID-19: Review of Epidemiology and Potential Treatments Against Evaluation of clinical methods for rating dyspnea Manual de Procedimientos SEPAR, 4 by SEPAR -Issuu Reference Equations for the Six-Minute Walk in Healthy Adults Prueba de la marcha de los 6 minutos Criterios y baremos para interpretar el -Inventario de Depresión de Beck-II‖ (BDI-II) Propiedades psicométricas de la escala revisada del impacto del evento estresante (IES-R) en una muestra espanola de pacientes con cancer STAI Cuestionario de Ansiedad Estado-Rasgo Aspectos Estadísticos del Cuestionario de Calidad de Vida relacionada con la salud Short Form -36 (SF-36) Acute respiratory distress syndrome: The Berlin definition Hospital de Barcelona COVID19-team, Long-term outcomes of patients following hospitalization for COVID-19: a prospective observational study Sequelae of the adult respiratory distress syndrome Impairment after adult respiratory distress syndrome. An evaluation based on American thoracic society recommendations Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS One-Year Outcomes in Survivors of the Acute Respiratory DistressMSyndrome The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors Brief Communication Correlation between Pneumonia Severity and Pulmonary Complications in Middle East Respiratory Syndrome The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and Health status Long-term sequelae of SARS: Physical, neuropsychiatric, and quality-of-life assessment 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records Posttraumatic stress symptoms and attitudetoward crisis mental health services amongclinically stable patients with COVID-19 in China The differential psychological distress of populations affected by the COVID-19 pandemic Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunològic mechanisms Post-traumatic stress disorder in adult victims of cluster munitions in Lebanon: A 10-year longitudinal study Post-traumatic stress disorder among survivors of the september 11 Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS) Abbreviations: BMI: Body mass index; COPD: Chronic obstructive pulmonary disease; CRP: Chain polymerase reaction; HIV: Human immunodeficiency virus; ICU: Intensive Care Unit; IQR: Interquartile range; LDH: Lactate dehydrogenase; LMWH: Low molecular weight heparin; LOS: length of hospital stay; OSAS: Obstructive sleep apnea syndrome SD: Standard deviation Solid organ transplantation, Hematopoietic stem cell transplantation Abbreviations: IQR: Interquartile range; SD: Standard deviation; mMRC: modified British Medical Research Council Table 3: 6MWT, radiological, and PFT results at follow-up tomography; IQR: Interquartile range; mMRC: modified British Medical Research Council; PE: Pulmonary embolism; PFT: Pulmonary function tests; SD: Standard deviation; SpO2: Peripheral oxygen saturation Abbreviations and definitions: BDI-2: Beck's index, a depression detection inventory; IES-R: Impact of Event Scale Revised, a posttraumatic stress assessment scale; PTSD: post-traumatic stress disorder